Bosch-Lenders Donna, Jansen Jesse, Stoffers Henri E J H Jelle, Winkens Bjorn, Aretz Karin, Twellaar Mascha, Schols Jos M G A, van der Kuy Paul-Hugo M, Knottnerus J André, van den Akker Marjan
Department of Family Medicine, Care and Public Health Research Institute (CAHPRI), Maastricht University, 6200 MD Maastricht, The Netherlands.
Department of Methodology and Statistics, Care and Public Health Research Institute (CAHPRI), Maastricht University, 6200 MD Maastricht, The Netherlands.
J Clin Med. 2021 Feb 5;10(4):600. doi: 10.3390/jcm10040600.
We conducted a comprehensive medication review at the patients' home, using data from electronic patient records, and with input from relevant specialists, general practitioners and pharmacists formulated and implemented recommendations to optimize medication use in patients aged 60+ years with polypharmacy. We evaluated the effect of this medication review on quality of life (QoL) and medication use. Cluster randomized controlled trial (stepped wedge), randomly assigning general practices to one of three consecutive steps. Patients received usual care until the intervention was implemented. Primary outcome was QoL (SF-36 and EQ-5D); secondary outcomes were medication changes, medication adherence and (instrumental) activities of daily living (ADL, iADL) which were measured at baseline, and around 6- and 12-months post intervention. Twenty-four general practices included 360 women and 410 men with an average age of 75 years (SD 7.5). A positive effect on SF-36 mental health (estimated mean was stable in the intervention, but decreased in the control condition with -6.1, = 0.009,) was found with a reduced number of medications at follow-up compared to the control condition. No significant effects were found on other QoL subscales, ADL, iADL or medication adherence. The medication review prevented decrease of mental health (SF36), with no significant effects on other outcome measures, apart from a reduction in the number of prescribed medications.
我们在患者家中进行了全面的药物审查,利用电子病历数据,并在相关专家、全科医生和药剂师的参与下,为60岁及以上使用多种药物的患者制定并实施了优化用药建议。我们评估了此次药物审查对生活质量(QoL)和用药情况的影响。采用整群随机对照试验(阶梯楔形设计),将全科医疗随机分配到连续三个步骤中的一个。患者在干预措施实施前接受常规护理。主要结局是生活质量(SF-36和EQ-5D);次要结局包括用药变化、用药依从性以及日常生活活动(ADL,iADL),在基线时以及干预后约6个月和12个月进行测量。24个全科医疗纳入了360名女性和410名男性,平均年龄75岁(标准差7.5)。与对照组相比,随访时发现干预对SF-36心理健康有积极影响(干预组估计均值稳定,而对照组下降了-6.1,P = 0.009),且用药数量减少。在其他生活质量子量表、ADL、iADL或用药依从性方面未发现显著影响。药物审查防止了心理健康(SF36)的下降,除了处方药物数量减少外,对其他结局指标均无显著影响。